Malignant Giant Cell Neoplasm — Trials

Malignant Giant Cell Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

107 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: 45.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05218408	CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type(CYNK001GBM02)	withdrawn	Phase 1 / Phase 2	0	Celularity IncorporatedINDUSTRY	0	Jun 8, 2026	clinicaltrials
NCT02055196	Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas	withdrawn	Phase 1	0	City of Hope Medical CenterOTHER	1	Jun 2, 2014